The Claim
In mouse hepatocytes, CRY1 promotes the ubiquitination and degradation of ChREBPα, and knockdown of CRY1 increases ChREBPα abundance, indicating that CRY1 acts as a negative regulator of ChREBPα stability.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In mouse liver cells, the protein CRY1 triggers the breakdown of ChREBPα, and reducing CRY1 levels results in higher amounts of ChREBPα.
See the scientific wording
In mouse hepatocytes, CRY1 promotes the ubiquitination and degradation of ChREBPα, and knockdown of CRY1 increases ChREBPα abundance, indicating that CRY1 acts as a negative regulator of ChREBPα stability.
In liver cells, CRY1 binds to ChREBPα and marks it for destruction by attaching ubiquitin molecules, which signals the cell's waste system to break it down. When CRY1 is removed or broken down, ChREBPα escapes destruction and builds up, turning on genes that make fat.
What the research says
1 studyStudy: DDB1 E3 ligase controls dietary fructose-induced ChREBPα stabilization and liver steatosis via CRY1
When mice eat a lot of sugar, a protein called CRY1 gets broken down, which lets another protein called ChREBPα build up and make more fat in the liver. When CRY1 is kept stable, ChREBPα goes down — so CRY1 normally stops ChREBPα from accumulating.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.